Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho Sells 5,742 Shares

Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho sold 5,742 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $36.83, for a total value of $211,477.86. Following the transaction, the general counsel now owns 189,295 shares of the company’s stock, valued at approximately $6,971,734.85. The trade was a 2.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Junlin Ho also recently made the following trade(s):

• On Thursday, January 16th, Junlin Ho sold 9,039 shares of Scholar Rock stock. The shares were sold at an average price of $44.20, for a total value of $399,523.80.

Scholar Rock Trading Up 3.0 %

SRRK traded up $1.14 on Thursday, hitting $39.15. The company had a trading volume of 670,911 shares, compared to its average volume of 911,591. Scholar Rock Holding Co. has a 12-month low of $6.76 and a 12-month high of $46.98. The business’s fifty day simple moving average is $41.94 and its 200 day simple moving average is $28.09. The company has a market cap of $3.67 billion, a PE ratio of -16.66 and a beta of 0.50. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SRRK. Creative Planning purchased a new position in shares of Scholar Rock during the third quarter valued at approximately $115,000. E. Ohman J or Asset Management AB boosted its position in shares of Scholar Rock by 32.6% during the third quarter. E. Ohman J or Asset Management AB now owns 122,000 shares of the company’s stock valued at $977,000 after buying an additional 30,000 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Scholar Rock by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock valued at $25,000 after buying an additional 514 shares during the period. abrdn plc raised its stake in shares of Scholar Rock by 28.2% during the third quarter. abrdn plc now owns 748,489 shares of the company’s stock valued at $5,995,000 after acquiring an additional 164,715 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Scholar Rock by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 15,393 shares of the company’s stock valued at $123,000 after acquiring an additional 6,023 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on SRRK shares. Wedbush restated an “outperform” rating and set a $47.00 price objective on shares of Scholar Rock in a research report on Wednesday, January 29th. Truist Financial raised their price objective on Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, November 25th. Finally, HC Wainwright raised their price objective on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.